Article Text

Download PDFPDF
Risk of multiple sclerosis during tumour necrosis factor inhibitor treatment for arthritis: a population-based study from DANBIO and the Danish Multiple Sclerosis Registry

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Contributors All authors made substantial contributions to the design of the work, interpretation of data and revising of the manuscript. BJ made the statistical analyses. LD drafted the manuscript. All authors gave final approval of the version published.

  • Funding The study is supported with grants from the Danish Rheumatism Association.

  • Competing interests FS reports grants and personal fees from Biogen, personal fees from Teva, grants and personal fees from Novartis, personal fees from Merck, grants and personal fees from EMD Serono, personal fees from Genzyme, outside the submitted work. LD has received honoraria from MSD and UCB for talks.

  • Ethics approval The project is entirely register-based, and the patients have not been contacted. Therefore, no approval by the Ethical Committees was needed according to Danish law. Approval by the Danish Data Protection Board Agency was obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.